Trefoil Therapeutics LLC

Tioga Research is a contract research organization (CRO) based in San Diego, CA, specializing in the research and early development of skin-applied formulations, including topical transdermal drugs and prestige cosmetic beauty care products. With a strong focus on formulation innovation and skin permeation screening, Tioga Research delivers R&D services to clients in the pharmaceutical, biotechnology, and personal beauty care industries worldwide. Founded in 2011 through a management buyout, Tioga Research has a rich history that dates back to 2002 when its predecessor company, fqubed, Inc., was formed. After a period of growth and expansion, Tioga Research became a wholly-owned subsidiary of Encube Ethicals in 2019. As a pure play CRO, Tioga Research collaborates with external sponsors and partners to develop cutting-edge skin delivery solutions and conduct skin permeation studies.Generated from the website

Gilman Biosciences LLC is a biotechnology company located in San Diego, California, specializing in a range of assay services including cell-based, biochemical, and biophysical assays. The company also offers high-throughput screening (HTS) assays, flow cytometry, and in vivo pharmacology solutions to support research and development in the life sciences sector. With a commitment to advancing scientific knowledge, Gilman Biosciences provides innovative tools and services designed to facilitate drug discovery and development. Their expertise and state-of-the-art technologies position them as a valuable partner for researchers in the biotechnology and pharmaceutical industries. Generated from the website

Plex Pharmaceuticals, Inc., based in San Diego, CA, is a scientifically-driven company focused on enhancing the lives of patients with complex diseases, particularly neurodegenerative disorders such as Parkinson's disease and glioblastoma. Their innovative drug discovery programs target misfolded proteins and employ cutting-edge technologies to develop therapies that address these pressing health challenges. In addition to their neurodegenerative research, Plex is working on non-surgical treatments for cataracts, which contribute significantly to global blindness, and has initiated efforts to develop inhibitors for CNS refractory tumors. By employing a unique fragment-based drug discovery approach, Plex aims to expedite the identification of new chemical entities that exhibit potential therapeutic efficacy. Generated from the website